0837 GMT - GSK needs to convince investors of a sustainable vaccine outlook after it cut the 2025 sales target of its jabs, Shore Capital analyst Sean Conroy says. The British pharma company now guides for a low single-digit decrease in vaccine sales for this year after a slowdown in the U.S., notably for its RSV shot Arexvy that missed consensus estimates by 18%, the analyst says. "Some tangible evidence the transient challenges facing Shingrix [shingles vaccine] and Arexvy can be navigated will likely be needed to reinstill the conviction in management's longer-term expectations for these," he says in a note. Shares are up 5.7% at 1,458.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.